OV secures new Drug Response Predictor for potential new drug candidate
Hoersholm, Denmark; July 5th, 2016 – Oncology Venture Sweden AB (OV:ST) announces the acquisition of a new DRP from Medical Prognosis Institute for a selected, undisclosed anti-cancer drug candidate. By this OV and MPI enhances their collaboration to improve the lives of cancer patients by developing new Personalized Medicine treatment options.Oncology Venture is finding anti cancer drugs that have achieved encouraging levels of complete and partial responses but not with a high enough response rate to secure approval. The drugs will, if they continue to fulfill OV’s requirements and are